CreativeOne Wealth LLC Increases Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

CreativeOne Wealth LLC boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 182.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,446 shares of the company's stock after purchasing an additional 2,873 shares during the period. CreativeOne Wealth LLC's holdings in Medpace were worth $1,484,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC acquired a new position in Medpace during the third quarter worth about $37,000. DT Investment Partners LLC acquired a new position in Medpace during the second quarter worth $41,000. Capital Performance Advisors LLP acquired a new position in Medpace during the third quarter worth $46,000. Ashton Thomas Private Wealth LLC acquired a new stake in Medpace in the second quarter valued at $52,000. Finally, International Assets Investment Management LLC purchased a new position in shares of Medpace in the second quarter valued at $61,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Stock Performance

Medpace stock traded up $1.67 during trading on Friday, reaching $340.63. The company had a trading volume of 214,814 shares, compared to its average volume of 284,415. The firm has a market capitalization of $10.59 billion, a price-to-earnings ratio of 29.83, a PEG ratio of 1.88 and a beta of 1.37. Medpace Holdings, Inc. has a 12-month low of $268.80 and a 12-month high of $459.77. The stock's 50 day moving average price is $337.82 and its two-hundred day moving average price is $371.41.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million for the quarter, compared to analysts' expectations of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.22 earnings per share. As a group, research analysts expect that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on MEDP shares. TD Cowen cut their target price on shares of Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Redburn Atlantic assumed coverage on Medpace in a research report on Monday, October 14th. They set a "buy" rating and a $404.00 price objective for the company. StockNews.com cut Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th. Truist Financial decreased their price objective on Medpace from $415.00 to $397.00 and set a "hold" rating on the stock in a research note on Monday, October 14th. Finally, Robert W. Baird upped their target price on shares of Medpace from $349.00 to $354.00 and gave the company a "neutral" rating in a report on Monday. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Medpace currently has an average rating of "Hold" and a consensus price target of $380.56.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.